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 Introduction 
 Overweight, obesity and associated metabolic disor-
ders such as diabetes and cardiovascular disorders are in-
creasing worldwide in a pandemic manner and affect also 
the fertile population, increasing the prevalence of com-
plications such as gestational diabetes (GDM) and hyper-
tensive disorders of pregnancy in particular  [1] . GDM is 
defined as glucose intolerance with first onset or recog-
nition during pregnancy. As glycemic changes become 
overt in the second half of pregnancy, the International 
Association of the Diabetes and Pregnancy Study Groups 
(IADPSG) has recommended a general screening for 
GDM using a 75-g oral glucose tolerance test (oGTT) at 
24–28 weeks of gestation  [2] , based on the findings
of the Hyperglycemia and Adverse Pregnancy Outcome 
(HAPO) study  [3] . However this metabolic disorder may 
already be present preconceptionally as impaired fasting 
glucose, impaired glucose tolerance or unrecognized pre-
existing diabetes mellitus type 2  [4] . Therefore, interna-
tional and national societies have recommended screen-
ing for these pre-existing metabolic disorders at the first 
antenatal visit by a fasting glucose measurement, 75-g 
oGTT, or by assessment of glycosylated hemoglobin 
(HbA1c)  [2, 5, 6] . Recently an association been first-tri-
mester HbA1c and GDM was reported  [7, 8] .
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 Abstract 
 Objective: The aim of this study was first to assess whether 
first-trimester serum concentrations of placental growth fac-
tor (PlGF) differ between patients with and without gesta-
tional diabetes (GDM) and second to test whether there is a 
correlation between glycosylated hemoglobin (HbA1c), a 
factor recently shown to be useful in predicting GDM, and 
PlGF.  Methods: PlGF was measured at 8–14 weeks with the 
Kryptor Immunoassay Analyzer (Brahms, Berlin, Germany). 
Absolute values were converted to multiples of the median 
using the software provided by the Fetal Medicine Foun-
dation London. GDM was diagnosed using internationally 
accepted criteria. HbA1c levels were quantified using the 
TOSOH G7 automated hemoglobin analyzer.  Results: From 
January to December 2014, 328 women were included in the 
study, 51 (15.5%) of whom developed GDM. First-trimester 
PlGF quantification does not discriminate between women 
at risk to develop GDM and controls, while HbA1c is able to 
do so. No correlation was found between PlGF and HbA1c. 
 Conclusion: Our findings do not lend support to the hypoth-
esis that early PlGF values are different in women who later 
develop GDM.  © 2015 S. Karger AG, Basel 
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 Placental growth factor (PlGF) belongs to the vascular 
endothelial growth factor (VEGF) family and is an angio-
genic factor that stimulates endothelial cells via fms-like 
tyrosine kinase-1. PlGF is expressed in trophoblastic cells 
and is suggested to play a vital role in the development of 
the placental vasculature  [9] . Hypoxia and inflammation 
alter angiogenic and anti-angiogenic factors in the pla-
centa  [10] , and maternal serum levels of PlGF are re-
duced in the first trimester of pregnancies that will de-
velop preeclampsia (PE) or small for gestational age in-
fants  [11, 12] . While earlier studies reported increased 
PlGF levels in pre-gestational diabetes (PGDM) and 
GDM  [13] , a recent publication demonstrated that in 
PGDM first-trimester maternal serum levels of PlGF are 
reduced  [14] , while yet another study showed again in-
creased PlGF levels in pregnancies that developed GDM 
 [15] .
 As there are still only limited and somehow also con-
flicting data available about first-trimester PlGF in GDM, 
the purpose of this study was to add data by comparing 
first-trimester PlGF in the general low-risk setting of our 
outpatient women who later developed GDM to those 
who did not, and to test whether a correlation exists be-
tween HbA1c and PlGF in the first trimester, as HbA1c is 
known to be increased in women who later develop GDM.
 Subjects and Methods 
 In this prospective study we included consecutive pregnant 
women attending for their first routine antenatal visit at 8–14 
weeks gestation who accepted to have a blood test for PlGF and 
HbA1c and a 75-g oGTT at 24–28 weeks gestation to diagnose 
GDM. As part of routine PE screening most women had a second 
PlGF measured at 11–14 weeks if the first one had been taken be-
fore 11 weeks gestation, as there are too limited existing data on 
the performance of PlGF drawn before 11 weeks for PE screening. 
Patients were recruited between January and December 2014 at the 
outpatient clinics of the Department of Obstetrics and Gynecology 
of the University Hospital Bern. Written informed consent was 
obtained from the women agreeing to participate in the study, 
which was approved by the Ethics Committee of the Canton of 
Bern. Exclusion criteria were pre-existing diabetes type 1 or 2 and 
also women with a first-trimester HbA1c value of  ≥ 6.5%.
 Maternal serum samples for PlGF were assayed with the 
Kryptor Immunoassay Analyzer (Brahms, Berlin, Germany) and 
results were expressed as absolute values and as multiples of the 
median (MoM) at 11–14 weeks only using The Fetal Medicine 
Foundation software (www.fetalmedicine.org). The lower detec-
tion limit was 3.6 pg/ml.
 HbA1c levels were quantified using the TOSOH G7 automated 
hemoglobin analyzer. The method principle is based on high-per-
formance liquid chromatography and is fully traceable IFCC stan-
dard in accordance with the European Union directive 98/79/EC 
on in vitro diagnostic medical devices. The HbA1c level is given in 
percent and SI units (mmol/mol)  [16] .
 According to current guidelines  [2, 3] the diagnosis of GDM 
was made when any of the following criteria were met on the 75-g 
oGTT: fasting plasma glucose  ≥ 5.1 mmol/l, or glucose  ≥ 10 mmol/l 
at 1 h, or glucose  ≥ 8.5 mmol/l 2 h. Blood was also drawn from the 
antecubital vein. Plasma glucose was estimated using the Roche 
Modular Analytics Chemistry Systems. The principle of the meth-
od is enzymatic utilizing hexokinase, which catalyzes the phos-
phorylation of glucose to glucose-6-phosphate  [17] .
 Statistical analyses were performed with GraphPad Prism ver-
sion 5.0 for Windows (GraphPad Software, San Diego, Calif., 
USA). Correlations were explored using the nonparametric Spear-
man rank test, while proportions were analyzed using Fisher exact 
or χ 2 test where appropriate. Mann-Whitney U test was used to 
compare continuous variables. Statistical significance was consid-
ered achieved when p was <0.05.
 Results 
 From January to December 2014 we included 328 
women in our study. Of those 51 (15.5%) fulfilled the cri-
teria for GDM and 277 served as controls. The demo-
graphic characteristics of the study population are depict-
ed in  table 1 . As expected, women with GDM were older 
and had a significantly higher body mass index (BMI) 
than those in the control group.
 310 women had PlGF assessed at 11–14 weeks (50 with 
GDM), 131 had an additional PlGF measurement at 8+0 
to 10+6 weeks gestation and 18 women had only a PlGF 
at 8–11 weeks, adding up to 149 patients with a PlGF mea-
surement before 11 weeks gestation (28 with GDM).
 HbA1c, always measured at the same time as the first 
drawn PlGF between 8+0 and 14 weeks gestation, was 
analyzed in 262 out of the 328 women.
 In  table 2 the results of first-trimester HbA1c and PlGF 
and PlGF MoM, dichotomized between women who did 
and those who did not develop GDM, are presented. PlGF 
was converted to MoM at 11–14 weeks only as there is
too limited information on PlGF MoM before that gesta-
tional age. There was no difference in gestational age or 
crown-rump length between the groups. No difference 
was found comparing first-trimester PlGF between the 
groups ( fig. 1 ), while HbA1c significantly discriminated 
between women who developed GDM and those who did 
not. There is no significant correlation between the abso-
lute values of PlGF and HbA1c (r = 0.09, p = 0.145) or 
between PlGF MoM and HbA1c (r = 0.08, p = 0.172). 
Similarly, no correlation was found between HbA1c and 
PlGF in the GDM group only (r = 0.20, p = 0.20) or in the 
control group only (r = 0.09, p = 0.55).
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 Discussion 
 The incidence of GDM in our collective is in accor-
dance with the described incidence of 17.5% (9.3–25.5%) 
in the IADPSG collaborating centers  [18] . Our findings 
do not show any difference of first-trimester PlGF con-
centrations or their MoM between pregnant women who 
later developed GDM and controls, contradicting a re-
cently published study that presented significantly higher 
first-trimester PlGF values in the GDM group  [15] . The 
Table 1.  Maternal demographic characteristics in comparison between the GDM and the control group
GDM (n = 51) Control (n = 277) p value 
Maternal age, years 32.22 ± 4.81 30.65 ± 5.52 0.034*
Maternal BMI 27.02 ± 6.32 23.1 ± 4.34 <0.0001*
Nulliparity 17 (33.3%) 145 (52.3%) 0.015*
Maternal ethnicity
White 33 (64.7%) 196 (70.6%) 0.409
Black 9 (17.6%) 43 (15.5%) 0.680
South Asian 6 (11.8%) 15 (5.4%) 0.114
East Asian 2 (3.9%) 18 (6.5%) 0.750
Mixed 1 (2.0%) 5 (1.8%) 1.000
Smoking 2 28 0.195
Chronic hypertension 1 4 0.573
Conception by ART 4 20 0.776
Outcomes
GA at delivery, weeks gestation 38.56 ± 1.90 39.54 ± 1.52 0.0007*
Birthweight, kg 3.130 ± 0.57 3.290 ± 0.50 0.194
LGA (>90th percentile) 6.9% 4.5% 0.634
 Comparisons between each outcome group with controls: all values are given as absolutes and percent or mean 
± SD. χ2 test and Fisher exact test for categorical variables and Mann-Whitney U test.
ART = Assisted reproductive technology; GA = gestational age; LGA = large for gestational age. * p < 0.05.
Table 2.  Distributions of biochemical parameters in the GDM and in the control group
GDM (n = 51) Control (n = 277) p value
Crown-rump length at 11 – 14 weeks, mm 64.49 ± 8.33 65.17 ± 8.23 0.602
GA at study inclusion, weeks gestation 10.8 ± 1.46 11.21 ± 1.53 0.094
PlGF, pg/ml
At 8 + 0 to 14 weeks 34.30 ± 18.65 36.10 ± 24.47 0.818
At 11 to 14 weeks 44.13 ± 21.23 44.95 ± 24.75 0.729
At 8 + 0 to 10 + 6 weeks 23.44 ± 8.41 24.13 ± 9.90 0.926
PlGF MoM at 11 to 14 weeks 1.05 ± 0.38 1.03 ± 0.48 0.454
HbA1c, % 5.39 ± 0.37 5.18 ± 0.28 0.0007*
 Comparisons between each outcome group with controls by Mann-Whitney U test: all values are given as 
mean ± SD.
GA = Gestational age. * p < 0.05.
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diagnosis of GDM in that study was also based on the 
HAPO criteria. However, no information was provided 
on how cases and controls were recruited.
 Ong et al.  [13] examined serum PlGF at 11–14 weeks 
gestation in 82 women with diabetic pregnancies consist-
ing of 32 women with PGDM and 50 high-risk women 
with GDM diagnosed with a 75-g oGTT and by applying 
the World Health Organization criteria. They also found 
increased serum PlGF in PGDM, at least in the non-insu-
lin-dependent subgroup. Newer data however found that 
serum PlGF was decreased in women with diabetes mel-
litus type 1 and in those with type 2 disease requiring 
treatment with insulin  [14] .
 Eleftheriades et al.  [15] explained their finding of higher 
first-trimester serum PlGF in pregnancies that later devel-
oped GDM by a hyperglycemia-induced alteration in pla-
cental angiogenesis. They based this assumption on a cor-
relation they found between fasting oGTT glucose values 
and first-trimester PlGF concentration. It is well estab-
lished that hyperglycemia affects angiogenesis  [19] . In dia-
betic retinopathy VEGF is upregulated, while decreased 
VEGF levels contribute to impaired wound healing in dia-
betes  [19] . Vasculogenesis and angiogenesis are essential 
for placental development and the VEGF family has been 
shown to play a key role  [20] . Moreover, a recent meta-
analysis of studies investigating postpartum placental his-
tology derived from pregnancies complicated by PGDM or 
GDM demonstrates that there is increased placental vol-
ume, higher incidence of villous immaturity and increased 
angiogenesis  [21] . Particularly the fetoplacental vascula-
ture and endothelium were shown to be susceptible to hy-
perglycemia  [22] . Fetal hyperinsulinism as a result of ma-
ternal hyperglycemia stimulates placental angiogenesis 
 [23] . Therefore, an increase in angiogenic markers such as 
PlGF might be a consequence of these alterations. How-
ever, PlGF is not altered in umbilical cord blood serum of 
neonates born to diabetic mothers  [24] . Moreover, Tsiak-
kas et al.  [14] found that first-trimester maternal PlGF se-
rum concentration was decreased in pregnancies compli-
cated by diabetes mellitus type 1, and also in type 2 when 
treatment with insulin was required. Using three-dimen-
sional sonography and power Doppler, it could be shown 
that first-trimester placental vascularization in pregnancies 
with PGDM is reduced, explaining in part the increased 
incidence of pregnancy-associated hypertensive disorders 
in diabetic pregnancies  [25] and the lower first-trimester 
maternal serum PlGF found in both PE  [26] and PGDM 
 [14] . However, these findings also remain contradictory, as 
Cohen et al.  [27] , examining women with PGDM, could 
not demonstrate a difference in PlGF in early pregnancy in 
women who developed PE compared to women who re-
mained normotensive or even compared to pregnant con-
trols without diabetes, while later in pregnancy there was a 
significant change among the different groups.
 A possible explanation for these divergent results in 
the literature and our findings might be that we excluded 
most of the possible cases with PGDM by screening for 
them using first-trimester HbA1c and excluding women 
with an HbA1c of  ≥ 6.5% according to the recommenda-
tion of the American Diabetes Association  [5] and the 
International Expert Committee on Diabetes  [28] . How-
ever, even after excluding PGDM, there remain some 
first-trimester metabolic changes in pregnancies that will 
develop GDM, as HbA1c was elevated in our and other 
studies  [7, 8] . The fact that we found no correlation be-
tween HbA1c and PlGF in the first trimester further lends 
support to the conclusion that PlGF in the first trimester 
is not a good marker for GDM.
 In the time of turning the pyramid of obstetric care 
 [29] , early screening for GDM with timely intervention is 
desirable. Besides HbA1c, several first-trimester markers 
for GDM such as adiponectin, SHBG, TNRF1 and PAI2 
have been described  [30] . While first-trimester maternal 
serum PlGF is an excellent marker for PE  [26] , our results 
could not confirm any use of first-trimester PlGF in 
screening for GDM.
 In conclusion, contradictory to previously published 
data, our results do not lend support to the theory that 
maternal serum PlGF is altered in the first trimester in 
pregnancies that will develop GDM. We also could not 
find any correlation between first-trimester HbA1c, in 
our study an early marker for GDM, and PlGF.
250
200
150
100
50
0
Control
Pl
G
F 
(p
g/
m
l)
GDM
 Fig. 1. Comparison of first-trimester PlGF concentrations in wom-
en with later GDM and in controls. 
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